Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mantle Cell Lymphoma (MCL): early-phase trial registry
7 of 10 indexed Mantle Cell Lymphoma (MCL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 7 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Mantle Cell Lymphoma (MCL): 10 US clinical trials tracked, 7 recruiting.
Mantle Cell Lymphoma (MCL) is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Acerta Pharma, running 2 of these trials.
Enrollment posture brief
Registry condition mantle-cell-lymphoma-mcl
OPEN 7 | RECR 70% | LATE 0 | EARLY 9 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Mantle Cell Lymphoma (MCL) lists 7 open slots (70% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mantle Cell Lymphoma (MCL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mantle Cell Lymphoma (MCL) is recruiting above its size-band peers.
7 of 10 indexed trials (70%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Mantle Cell Lymphoma (MCL) research.
Acerta Pharma accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Mantle Cell Lymphoma (MCL) enrolment sits around 124 participants.
Median target enrolment is 124 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.
-
Mantle Cell Lymphoma (MCL) research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT05131022
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06788652
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT04830137
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine
NCT04792489
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
NCT04186520
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
University of Colorado, Denver
NCT05098613
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics
NCT07121946
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma
NCT02213926
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
AstraZeneca
NCT05951959
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Acerta Pharma
NCT02717624
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Mantle Cell Lymphoma (MCL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mantle Cell Lymphoma (MCL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mantle Cell Lymphoma (MCL) page
10 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Mantle Cell Lymphoma (MCL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Acerta Pharma sponsors the most Mantle Cell Lymphoma (MCL) trials on record, review their full trial history before evaluating a specific study. See Acerta Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mantle Cell Lymphoma (MCL) condition card totals 10 registered trials; most-linked intervention ACP-196 (acalabrutinib); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.